A FIRM that develops antibody drugs to treat cancer has appointed a new executive director.
Milton Park-based Oxford BioTherapeutics has welcomed Dr John McHutchison, executive vice president in clinical research for Gilead Sciences, to its board.
Dr McHutchison has 20 years’ clinical and drug development experience, including Gilead’s programmes in liver diseases, haematology, oncology, inflammatory and respiratory diseases.
Past roles were at Duke University Medical Centre in North Carolina and the University of Southern California.
Dr McHutchison, who will also continue in his post with Gilead, said: “I am delighted to be joining OBT at this exciting time.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here